Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
NCT ID: NCT01008137
Last Updated: 2012-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2009-10-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Day 0-PANFLU.1; Day 21-ANFLU
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
H1N1 influenza A Vaccine (PANFLU.1)
H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Group 2: Day 0-ANFLU; Day 21-PANFLU.1
50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
H1N1 influenza A Vaccine (PANFLU.1)
H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Group 3: Day 0-PANFLU.1+ANFLU
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
H1N1 influenza A Vaccine (PANFLU.1)
H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
H1N1 influenza A Vaccine (PANFLU.1)
H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be able to show legal identity card for the sake of recruitment
3. Volunteers are able to understand and sign the informed consent
Exclusion Criteria
2. History of H1N1 vaccine or seasonal influenza vaccine administration
3. Women of pregnancy, lactation or about to be pregnant in 60 days
4. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
5. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
6. Autoimmune disease or immunodeficiency
7. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
8. Diabetes mellitus (type I or II), with the exception of gestational diabetes
9. History of thyroidectomy or thyroid disease that required medication within the past 12 months
10. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
11. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
12. Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
13. Seizure disorder other than:
* Febrile seizures under the age of two years old
* Seizures secondary to alcohol withdrawal more than 3 years ago, or
* A singular seizure not requiring treatment within the last 3 years
14. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
15. Guillain-Barre Syndrome
16. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
17. History of any blood products within 3 months before the dosing
18. Administration of any other investigational research agents within 30 days before the dosing
19. Administration of any live attenuated vaccine within 30 days before the dosing
20. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
21. Be receiving anti-TB prophylaxis or therapy currently
22. Axillary temperature \> 37.0 centigrade at the time of dosing
23. Psychiatric condition that precludes compliance with the protocol:
* Past or present psychoses
* Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
* Disorder requiring lithium
* Suicidal ideation occurring within five years prior to enrollment
24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinovac Biotech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Centers for Diseases Control and Prevention
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wu J, Zhong X, Li CK, Zhou JF, Lu M, Huang KY, Dong M, Liu Y, Luo FJ, Du N, Chui C, Liu LQ, Smith NM, Li B, Shi NM, Song LF, Gao Y, Wang DY, Wang X, Zhu WF, Yan Y, Li Z, Chen JT, McMichael AJ, Yin WD, Xu XN, Shu Y. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine. 2011 Jan 29;29(5):1009-16. doi: 10.1016/j.vaccine.2010.11.058. Epub 2010 Dec 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-PanFlu-4002
Identifier Type: -
Identifier Source: org_study_id